Email this article 
THE MEDICAL REPRESENTATIVES, OR DEBATES OF 2010S ABOUT PROMOTION OF MEDICATIONS
- Authors: Vishlenkova E.A.1,2, Zatravkin S.N.3,2,4
- Affiliations:
- The Freiburg Institute for Advanced Studies, 79104, Freiburg, Germany
- N. A. Semashko National Research Institute of Public Health, 105064, Moscow, Russia
- The State Budget Institution “The Research Institute of Health Care Organization and Medical Management of the Moscow Health Care Department”, 115088, Moscow, Russia
- Issue: Vol 31, No 4 (2023)
- Pages: 651-657
- Section: Articles
- URL: https://journal-nriph.ru/journal/article/view/1850
- DOI: https://doi.org/10.32687/0869-866X-2023-31-4-651-657
- Cite item
Abstract
The article considers the issue of the restrictions imposed by the government in the 2010s into process of introducing and promoting medications at the market by means of medical representatives. The government decided to formalize relationships of pharmaceutical manufacturers with consumers of medications. On the one hand, such a trend was occurring all over the world and was stimulated by social attacks at Big Pharma under slogan “the conflict of interests”. On the other hand, at the Russian pharmaceutical market, the restrictions of direct contacts of pharmaceutical manufacturers with physicians and and pharmaceutists were supported above all by national manufacturers of medicines. In the course of competition, vast army of Russian medical representatives was stigmatized that made many medics either to leave pharmaceutical market or to limit themselves to formal duties.
About the authors
E. A. Vishlenkova
The Freiburg Institute for Advanced Studies, 79104, Freiburg, Germany;
S. N. Zatravkin
N. A. Semashko National Research Institute of Public Health, 105064, Moscow, Russia; ;The State Budget Institution “The Research Institute of Health Care Organization and Medical Management of the Moscow Health Care Department”, 115088, Moscow, Russia
References
- Электронный ресурс: https://www.slideshare.net/Infor-media/schurov
- Давыдов С. А. A posteriori: полевые силы. Ремедиум. 2014;(6):32—7.
- Электронный ресурс: https://www.cossa.ru/149/99037/
- Электронный ресурс: http://archive.government.ru/special/docs/7859/
- Затравкин С. Н., Вишленкова Е. А., Игнатьев В. Г. Ренессанс российского фармрынка (2000—2004). Сообщение 2. Российские служители Фармы. Проблемы социальной гигиены, здравоохранения и истории медицины. 2023;(1):112—9.
- Электронный ресурс: http://www.medzapiski.ru/2013/01/cegedim-strategic-data.html
- Трищенко Д. А. Мифология лечения, ее спонсоры и протекторы. Знание. Понимание. Умение. 2018;(4):47—59.
- Чупандина Е. Е., Дагир С. Обзор основных подходов и особенностей в продвижении лекарственных препаратов на российском рынке. Медицина и образование Сибири. 2015;(5):32—6.
- Широкова И. Бизнес адаптируется к новым регуляторным условиям. Ремедиум. 2012;(7):28—33.
- Электронный ресурс: https://pharmvestnik.ru/content/articles/ljubovj-sizemova-tselj-zhizni-eto-zhiznj-s-tseljju.html
